Literature DB >> 29563746

Metastatic Renal Cell Cancer-Systemic Therapy.

Amit Joshi1, Arvind Sahu1, Vanita Noronha1, Vijay Patil1, Kumar Prabhash1.   

Abstract

Management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year to >2 years in mRCC.

Entities:  

Keywords:  Metastatic RCC; Pazopanib; Sunitinib; Targeted therapy

Year:  2018        PMID： 29563746      PMCID： PMC5856703          DOI： 10.1007/s13193-018-0721-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  58 in total

Review 1.  Interferon in metastatic renal cell carcinoma.

Authors:  S D Fosså
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

2.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

Authors:  Keith T Flaherty; Judith B Manola; Michael Pins; David F McDermott; Michael B Atkins; Janice J Dutcher; Daniel J George; Kim A Margolin; Robert S DiPaola
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

Review 5.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

6.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

7.  Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.

Authors:  Sebastian Attig; Jörg Hennenlotter; Graham Pawelec; Gerd Klein; Sven D Koch; Hanspeter Pircher; Susan Feyerabend; Dorothee Wernet; Arnulf Stenzl; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

8.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

9.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

Authors:  Brian I Rini; Bohuslav Melichar; Takeshi Ueda; Viktor Grünwald; Mayer N Fishman; José A Arranz; Angel H Bair; Yazdi K Pithavala; Glen I Andrews; Dmitri Pavlov; Sinil Kim; Eric Jonasch
Journal:  Lancet Oncol       Date:  2013-10-18       Impact factor: 41.316

10.  Spontaneous regression of metastatic renal cell carcinoma: case report.

Authors:  Katerina Lekanidi; Paraskevi A Vlachou; Bruno Morgan; Subramaniam Vasanthan
Journal:  J Med Case Rep       Date:  2007-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.